Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income towards Parent Company (2019 - 2025)

Historic Income towards Parent Company for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Income towards Parent Company rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13432.12%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • Latest data reveals that Keros Therapeutics reported Income towards Parent Company of -$7.3 million as of Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • Keros Therapeutics' Income towards Parent Company's 5-year high stood at $148.5 million during Q1 2025, with a 5-year trough of -$53.0 million in Q3 2024.
  • Moreover, its 5-year median value for Income towards Parent Company was -$29.7 million (2022), whereas its average is -$21.6 million.
  • Per our database at Business Quant, Keros Therapeutics' Income towards Parent Company plummeted by 32821.33% in 2022 and then soared by 44432.2% in 2025.
  • Keros Therapeutics' Income towards Parent Company (Quarter) stood at -$6.9 million in 2021, then crashed by 328.21% to -$29.7 million in 2022, then plummeted by 56.32% to -$46.5 million in 2023, then rose by 0.92% to -$46.0 million in 2024, then surged by 84.18% to -$7.3 million in 2025.
  • Its Income towards Parent Company was -$7.3 million in Q3 2025, compared to -$30.7 million in Q2 2025 and $148.5 million in Q1 2025.